Agios Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Net Income	-352.09	-231.8	1,605	-327.37	-411.47	Upgrade
Depreciation & Amortization	17.34	18.56	18.78	18.77	16.62	Upgrade
Share-Based Compensation	44.77	49.3	53.51	61.6	58.05	Upgrade
Other Operating Activities	-6.08	-145.53	-2,084.32	3.05	100.65	Upgrade
Operating Cash Flow	-296.06	-309.48	-407.32	-243.94	-236.16	Upgrade
Capital Expenditures	0.33	-3.92	-5.74	-14.11	-12.03	Upgrade
Acquisitions	0	131.78	0	0	0	Upgrade
Change in Investments	256.75	115.39	-548.42	90.66	103.61	Upgrade
Other Investing Activities	-17.5	-	1,803	-	-	Upgrade
Investing Cash Flow	239.58	243.26	1,249	76.55	91.58	Upgrade
Share Issuance / Repurchase	5.43	2.68	-765.19	11.32	289.72	Upgrade
Debt Issued / Paid	0	-0.33	-0.58	-0.34	-0.11	Upgrade
Other Financing Activities	-	-	-	261.52	289.61	Upgrade
Financing Cash Flow	5.43	2.35	-765.77	272.5	579.22	Upgrade
Net Cash Flow	-51.05	-63.87	75.69	46.51	10.43	Upgrade
Free Cash Flow	-295.74	-313.4	-413.06	-258.05	-248.18	Upgrade
Free Cash Flow Margin	-1102.55%	-2200.81%	-	-	-	Upgrade
Free Cash Flow Per Share	-5.31	-5.72	-6.83	-3.74	-4.14	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).